- Research article
- Open Access
Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations
BMC Structural Biology volume 9, Article number: 58 (2009)
The functional relevance of many of the recently detected JAK2 mutations, except V617F and exon 12 mutants, in patients with chronic myeloproliferative neoplasia (MPN) has been significantly overlooked. To explore atomic-level explanations of the possible mutational effects from those overlooked mutants, we performed a set of molecular dynamics simulations on clinically observed mutants, including newly discovered mutations (K539L, R564L, L579F, H587N, S591L, H606Q, V617I, V617F, C618R, L624P, whole exon 14-deletion) and control mutants (V617C, V617Y, K603Q/N667K).
Simulation results are consistent with all currently available clinical/experimental evidence. The simulation-derived putative interface, not possibly obtained from static models, between the kinase (JH1) and pseudokinase (JH2) domains of JAK2 provides a platform able to explain the mutational effect for all mutants, including presumably benign control mutants, at the atomic level.
The results and analysis provide structural bases for mutational mechanisms of JAK2, may advance the understanding of JAK2 auto-regulation, and have the potential to lead to therapeutic approaches. Together with recent mutation profiling results demonstrating the breadth of clinically observed JAK2 mutations, our findings suggest that molecular testing/diagnostics of JAK2 should extend beyond V617F and exon 12 mutations, and perhaps should encompass most of the pseudo-kinase domain-coding region.
Protein kinases play critical key roles in cellular signal transduction and can be activated by either phosphorylation or interaction with other proteins or ligands [1–4]. However, surprisingly little is known about protein-protein interactions involved in kinase activation processes. Scaffolds have been shown as allosteric regulators of kinases; symmetrical dimers of kinases could be involved in auto-phosphorylation regulation; and many protein kinases may be regulated via N-lobe interactions. In many protein kinases, activity is regulated by the coupling between the C-helix and regulatory domains [5–7]. In others, the catalytic domains act as their own regulatory regions [8, 9]. Recently, the MAP2K MEK6 was demonstrated to be auto-regulated via the formation of a symmetrical dimer .
Janus kinase 2 (JAK2) is a protein tyrosine kinase that transduces cellular signals through the JAK-STAT pathways [11, 12]. Deregulation of JAK2 is thought to be associated with hematopoietic disorders and oncogenesis [13–17], especially in patients with BCR-ABL-negative myeloproliferative neoplasms (MPNs) . However, the regulation mechanism of JAK2 remains elusive. Its kinase domain, JH1, is likely negatively regulated [19, 20] by the adjacent pseudo-kinase domain, JH2, probably in a manner similar to the mechanism of JAK3 regulation . Although other kinase/pseudo-kinase systems have been reported recently , the detailed interactions of JH1/JH2 are not well-understood, owing to a lack of available experimental structures. A theoretical structure model of the whole JAK2 assembly has been built using homology modeling methods and co-evolution data [23, 24]. In this model, the JH1 and JH2 domains face each other in an anti-symmetrical way; that is, the JH1 N-lobe contacts the JH2 C-lobe while the JH1 C-lobe contacts the JH2 N-lobe, with a helix-helix contact between the JH1 C-helix and the JH2 C-helix. This anti-symmetrical interface has not been reported in any other kinase/pseudo-kinase pair systems.
In 2005, studies identified the V617F mutation of the JAK2 JH2 domain in large numbers of patients with diverse clonal myeloid disorders [14, 17, 25–33]. The surprising frequency of this mutation suggests that V617 may play important roles in the auto-regulation of JAK2 and could become an important molecular target for new drug design. The V617F findings also imply that other mutations with similar phenotypes might have been ignored in the past; Ma et al  recent confirmed this idea through clinical evidence documenting mutations in exons 12 through 15 in patients with MPN-related phenotypes.
It has been suggested that the theoretical model outlined above may be able to explain the mutational effect of JAK2 V617F at the atomic level . Starting from this theoretical model, a homology-based structure has been used to explain the mutational effect of an exon-12 mutant . Homology modelling technique has also been applied to predict the mutational effect of an exon 12 deletion . Although those models demonstrate the relative position of V617 to the JH1/JH2 domain, further atomic level details, not seen in those models, are desperately needed to explain the constitutive activation caused by V617F.
Molecular dynamics simulations of biomolecules have provided useful information complementary to experimental evidence [37–39]. We recently reported 60-ns molecular dynamics simulations of the wild-type and V617F mutant JAK2 proteins, starting with the theoretical model mentioned above [23, 40]. Although the overall fold is maintained, the local conformations obtained from our simulations are significantly different from the starting theoretical homology model. More importantly, the simulation results now are able to explain the auto-regulation of JAK2 and the constitutive activation due to V617F in detail. There are three key groups of interactions between the JH1 and JH2 domains, holding JH1 in a closed inactive conformation. In the V617F mutant, F617 interacts with F595 and blocks other key interactions, resulting in loss of the JH1/JH2 interactions and forcing JH1 back to it open, active conformation (Figure 1).
Nevertheless, only the wild-type and one mutant (V617F) JAK2 were simulated in our previous study, hence the prediction of the JH1/JH2 domain interactions is not yet conclusive. Here we extend the simulations to newly discovered, clinically observed mutants, along with a set of presumably benign control mutants (Figure 2). Our findings here unveil the JAK2 auto-regulation mechanism in much greater detail, and simulation results provide a plausible explanation for the effects of each mutant at the atomic level. This study confirms the anti-symmetrical JH1/JH2 interface and, to our best knowledge, is the first to reconcile extensive clinically observed mutants through computational simulations of JAK2. These findings may provide the framework for rational drug design targeting various JAK2 mutants.
Results and discussion
JH1/JH2 Interface and Mutant Selection
The JH1/JH2 interface derived from our previous simulation work is summarized in Figure 1. Three key groups of interactions are shown: I-1 is the helix-helix interactions between the JH1 C-helix and the JH2 C-helix; I-2 is the interactions between the JH1 activation loop (A-loop) and the JH2 C-helix; and I-3 is the interactions between the activation loop of JH1 and a region of contact in JH2, including V617.
Ma et al  recently reported detection of several mutations in exons 12 to 15, based on analysis of approximately 20,000 clinical blood samples. Their findings suggested that molecular testing of JAK2 mutations should not be restricted to the V617F and exon 12 mutations, but perhaps should extend to most of the JH2 pseudo-kinase domain. Hence, the mutants used in our simulations were selected from the report of Ma et al (Figure 2): K539L in exon 12; R564L, L579F, H587N, and S591L in exon 13; 14-del (deletion of entire exon 14, corresponding to residues 592 to 622), H606Q, V617I, V617F, and C618R in exon 14, and L624P in exon 15. All were detected in patients with MPN. In addition, control simulations were performed using the K603Q/N667K double-mutant, V617C, and V617Y. The double-mutant should be benign because Q603/K667 is found in the JAK2 of other mammals, including pig, chicken, mouse, and rat; only human and pony show the "un-mutated" sequences (K603/N667). V617C and V617Y have never been reported in patients with MPN, despite the prevalence of V617F and experimental data demonstrating that V617C is benign .
Distortions of JH1/JH2 Interactions Due to Various JAK2 Mutations
Long time (60 ns each) full-scale molecular dynamics simulations were performed for each mutant, using simulation protocols described previously  and in the Methods section. The simulations performed here require at least 20 ns to reach steady-state, and the resulting mutational structure changes cannot be obtained by simple homology modelling methods .
The use of various distances between JH1 and JH2 proved useful in characterizing the JH1/JH2 interface in our previous work . However, the large number of distances needed to monitor the JH1/JH2 interface makes a succinct summary of the results difficult. Hence, instead of inter-atomic distances, we used the torsion angle between the C-helices of JH1 and JH2 to monitor the I-1 group of interactions. Figure 3 shows the relative torsion angle, defined as the dihedral angle between the carbonyl carbon atoms of residues R893, E900, S599, and E592, of all mutants from simulations,. I-1 interactions are severely changed in four mutants: K539L, S591L, V617I, and C618R. The data for 14-del is not shown since this mutant lacks the entire JH2 C-helix. I-1 interactions are more-or-less maintained in four mutants: L579F, K603N667K, V617C, and V617Y.
For I-2 and I-3 the van der Waals contact, a measure of inter-atomic interaction, was used to quantitatively analyze the interactions. The following van der Waals contacts were measured:
vdw(JH1:A, JH2:C): the van der Waals contact between the JH1 activation-loop (residues 995 to 1005) and the JH2 C-helix (resides 585 to 595). This term mainly measures the I-2 interactions.
vdw(JH1:A, JH2:V): the van der Waals contact between JH1 activation-loop and JH2 residues 614 to 619. This term mainly measures the I-3 interactions.
vdw(JH1:A, JH2:CV): the summation of the above two terms, vdw(JH1:A, JH2:C) and vdw (JH1:A, JH2:V). This term measures the total interactions of I-2 and I-3.
van der Waals contacts usually have negative values, indicating the molecular attracting force between atoms in molecules. A van der Waals contact larger in magnitude (with a negative sign) indicates that the two groups of measured atoms are closer; the van der Waals contact will be near 0 when two groups of measured atoms are far away from each other. Hence, the van der Waals contacts in Figure 4 can be thought of as the measure of the closeness between the JH1 activation loop and the JH2 domain (I-2 and I-3 interactions shown in Figure 1 lower panel). The total term, vdw(JH1:A, JH2:CV), indicates how much the JH1 activation loop is "locked" by the JH2 domain. When the contact is strong, there is no space for ATP or ligands to enter the active site and the JH1 kinase domain is thus locked and inactive. The results suggest that wild-type, K603Q/N667K, V617C, and V617I JAK2 have significantly larger contacts between the JH1 activation loop and the JH1 domain, while the K539L, R564L, S591L, 14-del, H606Q, V617F, and C618R mutants have very small contacts.
Table 1 summarizes the mutational effect annotations from simulations and confirms that the control mutants K603Q/N667K and V617C are likely to be benign, as well as the comparison with experimental/clinical evidence. This result is consistent with the fact that all mutants except K603Q/N667K, V617C, and V617Y correspond to MPN-positive cases. V617C in fact has been shown to be benign experimentally . In addition, the simulation results of V617F and K539L suggest that both are deleterious mutants and cause significant changes in the JH1/JH2 interface, well in line with clinical data showing that both are transforming [17, 43, 44]. Hence V617F and K539L can be considered as the positive control simulations. Detailed analyses and the origins of the mutation effects for each mutant will be discussed in the following sections.
Origins of mutational effects
Figure 5 shows representative snapshots for mutations at the 617 position. In wild-type JAK2, the JH1 activation loop is in contact with V617 and nearby residues, as well as the residues of JH2 C-helix, especially F595 and S591. I-1, I-2, and I-3 interactions are well preserved (Figure 4 and Figure 5). In V617F, F617 interacts with F595 and hence blocks the contacts between the JH1 activation loop and the JH2 C-helix. The JH1 activation loop is wide-open and highly accessible. I-1, I-2, and I-3 interactions are both lost (Figure 4 and Figure 5). This mutation has been discussed in detail in our previous study .
V617C is very similar to wild-type and all three sets of interactions (I-1, I-2, and I-3) are well preserved. V617C is thus a benign mutation, consistent with a recent experimental study . However, close examination of the local conformation indicates that C617 binds to the JH1 activation loop in a slightly different way. In WT, V617 mainly contacts with hydrophobic residues V1000, L1001, and P1002, while in V617C, C617 slowly moves to form polar interactions with residues 1003 to 1005 after 40 ns. This implies that while V617C does not cause constitutive activation, it may induce different phosphorylation patterns at the JH1 activation loop.
V617I is similar to wild-type in that I-2 and I-3 are maintained; that is, the JH1 activation loop is locked by the JH2 C-helix and V617 region residues. However, the bulky side chain of I617 pushes the JH1 activation loop toward the I-1 interface (JH1 C-helix/JH2 C-helix) and breaks the I-1 interactions. This may imply that a mutation with a large non-polar side-chain will yield similar results.
In V617Y (Figure 4 and Figure 5), Y617 also interacts with F595 and blocks the contacts between the JH1 activation loop and JH2 C-helix in a way very similar to V617F, in that the I-2 interactions (vdw [JH1:A, JH2:C]) are severely damaged. However, while its aromatic ring interacts with F595, the polar tail of Y617 moves near the interface between the JH1 C-helix and the JH2 C-helix, forming multiple hydrogen-bonds with nearby water molecules and with the JH1 activation loop (not shown), indicated by the small decrease in the I-3 interactions (vdw [JH1:A, JH2:V]). The result is that the JH1/JH2 interface is not as open as with F617. Based on the results of V617F and V617Y, V617W would have mutational effects similar to those of V617F, since it will also interact with F595 and does not have a polar tail like V617Y. This prediction is in fact consistent with recent observations .
The simulation results of V617 mutants demonstrate the important roles that residue 617 side chain plays in JH1/JH2 interactions. An aromatic ring side chain (V617F,Y) interacts with F595 to block the JH1 activation contact; a polar side chain (V617C) could change the local conformation and form a contact with K1005; and a large hydrophobic side chain (V617I) could interfere with the I-1 interactions.
In our previous study, we predicted that a mutation of S591 would break the polar interaction between S591 and Q1003 and hence affect the I-1 interactions. S591L was indeed observed in MPN patients recently . As shown in Figure 6, S591L has the same conformation as wild-type JAK2 at the very beginning of simulations (0 ns). At 44 ns, the JH1/JH2 interface is well formed in wild-type JAK2; in S591L JAK2, L591 forms hydrophobic contacts with nearby F595, L583, and A586. The I-1 interface is totally distorted, and the I-2 and I-3 falls apart as well. The result suggests that S591L will be a severely deleterious mutation and will cause constitutive activation of JAK2. The mechanism may reflect the hydrophobic nature of the L591 residue in that its side chain is repelled by the JH1/JH2 interface region, which is highly solvent-accessible and is surrounded with many water molecules.
K539L, C618R, and R564L
In the simulation-derived structure (Figure 1), V617 is positioned to contact the JH1 activation loop, a result of the fold of the JH2 domain. A mutation altering the JH2 fold will likely affect the V617 position and hence the JH1/JH2 interface. V617 is located at the joint of the β-4 and β-5 sheets (Figure 7). These two beta sheets are connected through the hydrogen bonding network and anchored by surrounding residues. Figure 7 shows parts of those surrounding residues. A loop from K539 to D544 forms few interactions with the β-4 sheet: D620 is in a highly charged environment formed by K539 and R541. C616 and C618, through some water bridges, point to the charged environment formed by R564, E543, and D544. Simulation results indicate that mutations of the relevant residues significantly disrupt the local conformation for the following reasons (Figure 7):
In K539L, L539 moves away from the highly-charged region of D620 and R541 and moves E543 and D544 downward.
In R564L, the strong salt bridge interactions between R564 and E543/D544 are completely lost.
In C618R, R618 moves toward E543/D544 and forms strong salt bridges with them, disrupting the interaction between R564 and E543.
These conformational changes are consistent with the analysis of the JH1/JH2 interface (Figure 1, Figure 3, and Table 1). The results also suggest that the loop of residues 539 to 544 is important to support the local conformation near V617.
L579F, L624P, and H606Q
Similarly, L624 is located in the β-5 sheet, L579 is located in a nearby beta-sheet, and H606Q is in the loop connecting the JH2 C-helix and β-4 sheet (Figure 8). All three mutants cause conformational changes in this region. In L579F, F579 interacts with nearby F628, changes the surrounding packing pattern, and causes the conformational changes between the β-4 and β-5 sheets. In L624P, P624 enforces a conformational change of the β-5 sheet because of the rigid conformation of proline. L579F and L624P cause local conformational changes but their mutational effects are relatively indirect and not as deleterious, consistent with the simulation results (Figure 3, and Figure 4).
H606Q disrupts the interactions between the residue 606 sidechain and the L604/L609 backbones, affecting the conformation of the loop (604 to 609) connecting the JH2 C-helix and the β-4 sheet and thus changing the position of V617 relative to the C-helix. This finding is consistent with the simulation results in that the I-2 and I-3 interactions are damaged severely (Figure 4) when the I-1 is moderately distorted (Figure 3). In this region, E627 and K688 form strong salt bridge interactions to maintain the local conformation. Mutations of these two positions or nearby residues may also result in strong deleterious effects.
In this mutant the entire exon-14 coding region is deleted (residues 593 to 622). Almost every residue of the JH1/JH2 interface is missing, except S591 and E952. Simulation results (Figure 3 and Figure 4) suggest that this mutant will very likely cause JAK2 constitutive activation.
H587N and K603Q/N667K Double-Mutant
Because H587 is exposed to solvent and H587N would constitute a polar-to-polar conserved mutation, this variation might not be expected to cause a significant mutational effect. However, simulation results indicate that H587N modifies hydrogen bond pattern of the 587 residue. The sidechain of H587 normally forms hydrogen bonds with the backbones of Y590 and S591; in the N587 variant, the S591 backbone forms hydrogen bonds with the backbone of N587 (Figure 9). The altered hydrogen bond pattern causes rotation of the JH2 C-helix and additional changes in the pattern of the hydrogen bond network between E890, R588, and N589. In N587, E890 now forms a new hydrogen bond with E589 and brings itself closer to the JH2 C-helix. The result is the disruption of the I-1 interactions, indicating that H587N is a deleterious mutation.
As mentioned above, the K603Q/N667K double-mutant exists in the JAK2s of other mammals, including pig, chicken, mouse, and rat; only human and pony sequences show the "un-mutated" sequences (K603/N667). Not surprisingly, the simulation results suggest that K603/N667 will be a benign mutation (Figure 3, Figure 4, and Table 1). However, the detailed I-1 interaction patterns are significantly different from those of wild-type JAK2 (Figure 9). Wild-type has the following hydrogen bonding or salt bridge pairs: K603/E900, E596/E896, E596/R893, E592/R588, and R588/E890. In K603Q/N667K, there is no salt bridge between Q603 and E900, since Q603 lacks a positive charge; Q603 forms a hydrogen bond with S904 instead, causing significant rearrangements of the interactions. Hydrogen bonding or salt bridge pairs in K603/QN667K JAK2 include Q603/S904, E596/R893, E896/R893, E900/R893, E592/R897, and R588/E890. The interactions in K603Q/N667K JAK2 seem stronger than in wild-type. Indeed, the fluctuation (standard deviation) of the torsion angle between JH1/JH2 C-helices is much smaller in K603Q/N667K than in wild-type (Figure 3). This finding suggests that K603Q/N667K could have more stable I-1 interactions and may imply that mutational studies based on murine models could lead to different results, especially when considering the effect on the I-1 interactions. For example, H587 is no longer held by the side chains of Y590 and S591 in K603Q/N667K, which may imply that a mutation at the 587 position, such as H587N, would have different effect in the K603Q/N667K mutant than in wild-type JAK2.
In summary, we report a set of molecular dynamics simulations on clinically observed mutants along with control mutants. The results, which could not be obtained from simple homology-based models or other static structures, are consistent with available clinical and experimental evidence. Although the JH1/JH2 interface is derived from simulations and should be considered as putative, the anti-symmetrical JH1/JH2 interface seems very reasonable and we are able to explain the mutational effect for each mutant at atomic levels, including the presumably benign mutants V617C and K603Q/N667K. The results and analysis provide likely structural explanations of mutational mechanisms and may advance the understanding of JAK2 auto-regulation. It is clear that our simulation-derived structures are capable of reproducing all available experimental/clinical mutational data. However, it is important to emphasize that such success does not prove that these structures are correct before experimental structures are available.
Our simulation findings together with recent JAK2 mutation profiling results  suggest that molecular testing of JAK2 mutations should not be restricted to V617F and exon 12 mutations [43–45], but perhaps should extend to most of the pseudo-kinase domain coding region as well, especially the relevant residues shown in our atomic-level analysis.
The only currently available theoretical structure model of the entire JAK2 protein, built using homology modeling methods, and co-evolution data [23, 40], were used as the starting point. The original papers of this model have been cited over 30 times and have been extensively used to rationalize experimental/clinical evidence. Although it is relatively old, it is widely accepted in the JAK2 community, and has been utilized to explain structural effects [36, 46], and has even been used as the starting model for other system (JAK1). The domain arrangement of this model is the current consensus accepted by those who are working on JAK2 crystal structures . The inter-domain interaction between JH1 and JH2 was further verified by the DComplex server http://sparks.informatics.iupui.edu/czhang/complex.html and the reported binding free energy between JH1 (residues 840 to 1129) and JH2 (residues 543 to 839) is -11.21 Kcal/mol for this homology model; while the value for the MD-simulation structure at 44 ns snapshot (WT) is -12.84 Kcal/mol. Both show that the JH1/JH2 inter-domain arrangement is reasonable. Based on the above reasons, we chose this model as our starting structure for all subsequent simulations.
Homology Modelling for 14-del
The MODELLER software package (version 9v5)  was used to build the homology model for the 14-del variant; The sequences of 14-del JAK2 (deletion of residues S593 to N622) and wild-type JAK2 proteins were aligned using the ClustalW web server http://www.ebi.ac.uk/Tools/clustalw/index.html, resulting in a 30-residue gap between residue 592 and 623 (WT numbering). The aligned WT and 14-del sequences were used as the input alignment for MODELLER, and the WT structure mentioned above as the template structure. The modeller.automodel module in MODELLER with default parameters was used to build one model without any additional restraints. This MODELLER-generated 14-del structure then was used as the starting structure for the subsequent MD simulation of the 14-del variant.
Molecular Dynamics Simulations
The homology-based model of the whole JAK2 assembly  was used as the initial structure for the wild-type and all mutant simulations, except for the 14-del mutant as described in the previous section. The following preparation steps were performed prior to molecular dynamics simulations, using the VMD software package (version 1.8.6, http://www.ks.uiuc.edu/Research/vmd/). All ionizable residues were considered in the standard ionization state at neutral pH condition. The whole protein then was put in a water box, filled with TIP3P water, with at least 15 Å buffer distance in any direction, resulting in a roughly 130 Å × 120 Å × 90 Å box containing JAK2 and water molecules. Sodium and chloride ions were added randomly in space (but were kept initially at least 4.7 Å away from any solute atoms) to reach the physiological concentration of sodium ions (0.14 M) and overall electric neutrality. The complex was oriented to align its longest axis with the x-axis of the water box, and its center of mass was placed at the center of the box. Water molecules less than 1.4 Å from any atom of the complex were removed. The resulting system contained 138,824 atoms for the wild-type (JAK2:17,657; water: 121,062; sodium ion: 53; chloride ion: 52) and 130,007 atoms for the 14-del mutant (JAK2:17,209; water: 112,698; sodium ion: 49; chloride ion: 49).
All molecular dynamics (MD) simulations were performed using the NAMD package (version 2.6)  with the CHARMM27 force field [55, 56]. Default parameters and settings were used except as mentioned below. Periodic boundary conditions were used along with the isothermal-isobaric ensemble (NPT) at 1 atm and 298 K using an extended system pressure algorithm  with effective mass of 500.0 amu and Nosé-Hoover thermostat[58, 59] with effective mass of 1000.0 kcal/mol-ps2. The smooth particle mesh Ewald (PME) method  was employed. A B-spline interpolation order of 4 was used, combined with 120, 120, and 75 FFT grid points for the lattice directions x, y, and z, respectively. Non-bonded interactions were treated using an atom-based cutoff of 12 Å with switching van der Waals potential beginning at 10 Å. Numerical integration was performed using the leap-frog Verlet algorithm with 1 fs time step. Covalent bond lengths involving hydrogen were constrained using the SHAKE algorithm [61, 62].
The following procedure was used prior to the data collection for the wild-type and 14-del mutant. All atoms of the protein complex were first restrained at their starting structure positions with a force constant of 50 kcal/mol/Å2. Water and ion molecules were first energy-optimized and then underwent the following simulation annealing to ensure the proper equilibration. The temperature was increased from 0 K to 600 K at the rate of 1 K per ps and maintained at 600 K for 500 ps. Then the temperature was decreased to 300 K at the rate of 1 K per ps and maintained at 300 K for 500 ps. The system then was kept at 300 K for 4 ns. The total equilibration time was about 5 ns in this step. The system was next brought down to 0 K and the same 5 ns equilibration was repeated, resulting in an equilibration simulation of total 10 ns for water molecules and ions. The water/ion-equilibrated systems, both of the wild-type and 14-del, then were used as the starting point for the production simulations. All mutants, except 14-del, were created from the water/ion-equilibrated wild-type structure through the VMD package. For all simulations, the restraint force constant then was gradually reduced to 3 kcal/mole/Å2 during a 500-ps period, followed by 2,000-step energy-minimization for all atoms and a 300-ps heating period with the temperature increased from 0 to 300 K at the rate of 1 K per ps. Production MD simulations of 60 ns were then performed for all simulations without any constraint or restraint. Trajectories were saved at the frequency of 1 ps.
Figure 10 shows the heavy atom root-mean-squared deviation (RMSD, in Å, relative to the initial strucuture) of JH1 domain (defined as residue 840 to 1129), JH2 domain (defined as residue 543 to 839), and of JH1/JH2 together (defined as residue 543 to 1129) for the wild-type JAK2. RMSD is commonly used as an indicator of stability of MD simulations. The RMSD curves of individual JH1 and JH2 domains indicate simulations of both domains are stable after ~20 ns. The RMSD curve of combined JH1/JH2 indicates that the relative positions of JH1/JH2 as well as their tertiary interactions are also stable after ~20 ns. Simulations of other mutants exhibit similar behaviours. Those results suggest that the simulations reported here are converged and the corresponding derived analysis is reliable in the timescale simulated.
Pellicena P, Kuriyan J: Protein-protein interactions in the allosteric regulation of protein kinases. Curr Opin Struct Biol 2006, 16(6):702–709. 10.1016/j.sbi.2006.10.007
Taylor SS, Ghosh G: Protein kinases: Catalysis and regulation. Curr Opin Struct Biol 2006, 16(6):665–667. 10.1016/j.sbi.2006.11.001
Nolen B, Taylor S, Ghosh G: Regulation of protein kinases; controlling activity through activation segment conformation. Mol Cell 2004, 15(5):661–675. 10.1016/j.molcel.2004.08.024
Hubbard SR: Protein tyrosine kinases: autoregulation and small-molecule inhibition. Curr Opin Struct Biol 2002, 12(6):735–741. 10.1016/S0959-440X(02)00383-4
Tesmer VM, Kawano T, Shankaranarayanan A, Kozasa T, Tesmer JJG: Snapshot of activated G proteins at the membrane: the Galphaq-GRK2-Gbetagamma complex. Science 2005, 310(5754):1686–1690. 10.1126/science.1118890
Schindler T, Sicheri F, Pico A, Gazit A, Levitzki A, Kuriyan J: Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol Cell 1999, 3(5):639–648. 10.1016/S1097-2765(00)80357-3
Xu W, Doshi A, Lei M, Eck MJ, Harrison SC: Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 1999, 3(5):629–638. 10.1016/S1097-2765(00)80356-1
Dar AC, Dever TE, Sicheri F: Higher-order substrate recognition of eIF2alpha by the RNA-dependent protein kinase PKR. Cell 2005, 122(6):887–900. 10.1016/j.cell.2005.06.044
Gay LM, Ng H-L, Alber T: A conserved dimer and global conformational changes in the structure of apo-PknE Ser/Thr protein kinase from Mycobacterium tuberculosis. J Mol Biol 2006, 360(2):409–420. 10.1016/j.jmb.2006.05.015
Min X, Akella R, He H, Humphreys JM, Tsutakawa SE, Lee S-J, Tainer JA, Cobb MH, Goldsmith EJ: The Structure of the MAP2K MEK6 Reveals an Autoinhibitory Dimer. Structure 2009, 17(1):96–104. 10.1016/j.str.2008.11.007
Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW: Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 2002, 285(1–2):1–24. 10.1016/S0378-1119(02)00398-0
Rawlings JS, Rosler KM, Harrison DA: The JAK/STAT signaling pathway. J Cell Sci 2004, 117(Pt 8):1281–1283. 10.1242/jcs.00963
James C, Delhommeau F, Marzac C, Teyssandier I, Couédic JPL, Giraudier S, Roy L, Saulnier P, Lacroix L, Maury S, et al.: Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 2006, 20(2):350–353. 10.1038/sj.leu.2404069
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, Boggon TJ, Wlodarska I, Clark JJ, Moore S, et al.: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7(4):387–397. 10.1016/j.ccr.2005.03.023
Skoda R: Update on the impact of the JAK2 mutation on signalling pathways in myeloproliferative disorders. Eur J Haematol Suppl 2007, (68):5–8. 10.1111/j.1600-0609.2007.00935.x
Skoda R: The genetic basis of myeloproliferative disorders. Hematology Am Soc Hematol Educ Program 2007, 2007: 1–10.
Morgan KJ, Gilliland DG: A role for JAK2 mutations in myeloproliferative diseases. Annu Rev Med 2008, 59: 213–222. 10.1146/annurev.med.59.061506.154159
Pikman Y, Levine RL: Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders. Curr Opin Oncol 2007, 19(6):628–634. 10.1097/CCO.0b013e3282f0e20c
Saharinen P, Silvennoinen O: The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 2002, 277(49):47954–47963. 10.1074/jbc.M205156200
Saharinen P, Takaluoma K, Silvennoinen O: Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 2000, 20(10):3387–3395. 10.1128/MCB.20.10.3387-3395.2000
Chen M, Cheng A, Candotti F, Zhou YJ, Hymel A, Fasth A, Notarangelo LD, O'Shea JJ: Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol Cell Biol 2000, 20(3):947–956. 10.1128/MCB.20.3.947-956.2000
Kornev AP, Taylor SS: Pseudokinases: Functional Insights Gleaned from Structure. Structure 2009, 17(1):5–7. 10.1016/j.str.2008.12.005
Lindauer K, Loerting T, Liedl KR, Kroemer RT: Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng 2001, 14(1):27–37. 10.1093/protein/14.1.27
Giordanetto F, Kroemer RT: Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. Protein Eng 2002, 15(9):727–737. 10.1093/protein/15.9.727
Nelson ME, Steensma DP: JAK2 V617F in myeloid disorders: what do we know now, and where are we headed? Leuk Lymphoma 2006, 47(2):177–194. 10.1080/10428190500301348
Tefferi A, Gilliland DG: The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc 2005, 80(7):947–958. 10.4065/80.7.947
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, et al.: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365(9464):1054–1061.
James C, Ugo V, Couédic J-PL, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, et al.: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434(7037):1144–1148. 10.1038/nature03546
Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352(17):1779–1790. 10.1056/NEJMoa051113
Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, Zhao ZJ: Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005, 280(24):22788–22792. 10.1074/jbc.C500138200
Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, et al.: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005, 106(6):2162–2168. 10.1182/blood-2005-03-1320
Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A: The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 2005, 106(4):1207–1209. 10.1182/blood-2005-03-1183
Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ, Gilliland DG, Tefferi A: JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005, 131(2):208–213. 10.1111/j.1365-2141.2005.05764.x
Ma W, Kantarjian H, Zhang X, Yeh C-H, Zhang ZJ, Verstovsek S, Albitar M: Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J Mol Diagn 2009, 11(1):49–53. 10.2353/jmoldx.2009.080114
Kaushansky K: On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood 2005, 105(11):4187–4190. 10.1182/blood-2005-03-1287
Albiero E, Madeo D, Ruggeri M, Bernardi M, Giorgetti A, Rodeghiero F: Loss of the JAK2 intramolecular auto-inhibition mechanism is predicted by structural modelling of a novel exon 12 insertion mutation in a case of idiopathic erythrocytosis. Br J Haematol 2008, 142(6):986–990. 10.1111/j.1365-2141.2008.07180.x
Kollman PA, Weiner S, Seibel G, Lybrand T, Singh UC, Caldwell J, Rao SN: Modeling complex molecular interactions involving proteins and DNA. Ann N Y Acad Sci 1986, 482: 234–244. 10.1111/j.1749-6632.1986.tb20954.x
Karplus M, McCammon JA: Molecular dynamics simulations of biomolecules. Nat Struct Biol 2002, 9(9):646–652. 10.1038/nsb0902-646
Karplus M, Kuriyan J: Molecular dynamics and protein function. Proc Natl Acad Sci 2005, 102(19):6679–6685. 10.1073/pnas.0408930102
Giordanetto F, Kroemer RT: Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. Protein Eng 2002, 15(9):727–737. 10.1093/protein/15.9.727
Dusa A, Staerk J, Elliott J, Pecquet C, Poirel HA, Johnston JA, Constantinescu SN: Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2. J Biol Chem 2008, 283(19):12941–12948. 10.1074/jbc.M709302200
Lee T-S, Ma W, Zhang X, Giles F, Kantarjian H, Albitar M: Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations. Cancer 2009, 115: 1692–1700. 10.1002/cncr.24183
Pietra D, Li S, Brisci A, Passamonti F, Rumi E, Theocharides A, Ferrari M, Gisslinger H, Kralovics R, Cremonesi L, et al.: Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008, 111(3):1686–1689. 10.1182/blood-2007-07-101576
Tefferi A: JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma 2008, 49(3):388–397. 10.1080/10428190801895360
Karow A, Waller C, Reimann C, Niemeyer CM, Kratz CP: JAK2 mutations other than V617F: a novel mutation and mini review. Leuk Res 2008, 32(2):365–366. 10.1016/j.leukres.2007.02.018
Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, et al.: JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis. N Engl J Med 2007, 356(5):459–468. 10.1056/NEJMoa065202
Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L, Ariola C, Fodale V, Clappier E, Paoloni F, et al.: Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008, 205(4):751–758. 10.1084/jem.20072182
Lucet IS, Fantino E, Styles M, Bamert R, Patel O, Broughton SE, Walter M, Burns CJ, Treutlein H, Wilks AF, et al.: The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 2006, 107(1):176–183. 10.1182/blood-2005-06-2413
Liu S, Zhang C, Zhou H, Zhou Y: A physical reference state unifies the structure-derived potential of mean force for protein folding and binding. Proteins 2004, 56(1):93–101. 10.1002/prot.20019
Fiser A, Sali A: Modeller: generation and refinement of homology-based protein structure models. Methods Enzymol 2003, 374: 461–491. full_text
Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, et al.: Clustal W and Clustal X version 2.0. Bioinformatics 2007, 23(21):2947–2948. 10.1093/bioinformatics/btm404
Humphrey W, Dalke A, Schulten K: VMD: Visual Molecular Dynamics. J Mol Grapics 1996, 14: 33–38. 10.1016/0263-7855(96)00018-5
Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML: Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983, 79: 926–935. 10.1063/1.445869
Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kalé L, Schulten K: Scalable Molecular Dynamics with NAMD. J Comput Chem 2005, 26: 1781–1802. 10.1002/jcc.20289
Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M: Charmm: a program for macromolecular energy minimization and dynamics calculations. J Comput Chem 1983, 4: 187–217. 10.1002/jcc.540040211
MacKerell AD Jr, Brooks B, CL Brooks I, Nilsson L, Roux B, Won Y, Karplus M: CHARMM: the energy function and its parameterization with an overview of the program. In Encyclopedia of Computational Chemistry. Volume 1. Edited by: Schreiner PR. Chichester: John Wiley & Sons; 1998:271–277.
Andersen HC: Molecular dynamics simulations at constant pressure and/or temperature. J Chem Phys 1980, 72: 2384–2393. 10.1063/1.439486
Hoover WG: Canonical dynamics: Equilibration phase-space distributions. Phys Rev A 1985, 31(3):1695–1697. 10.1103/PhysRevA.31.1695
Nose S, Klein ML: Constant pressure molecular dynamics for molecular systems. Mol Phys 1983, 50(5):1055–1076. 10.1080/00268978300102851
Essmann U, Perera L, Berkowitz ML, Darden T, Hsing L, Pedersen LG: A smooth particle mesh Ewald method. J Chem Phys 1995, 103(19):8577–8593. 10.1063/1.470117
Allen MP, Tildesley DJ: Computer Simulation of Liquids. Oxford: Oxford University Press; 1987.
Ryckaert JP, Ciccotti G, Berendsen HJC: Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes. J Comput Phys 1977, 23: 327–341. 10.1016/0021-9991(77)90098-5
We are greatly thankful to Dr. Romano Kroemer and Dr. Thomas Loerting for providing the atomic coordinates of their homology model of JAK2. This work was partially supported by the computational resources of Minnesota Supercomputing Institute (MSI) and the National Center for Supercomputing Applications under MCB090117 through NCSA's TeraGrid mechanism. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
TL designed and performed all calculations and data analysis, and wrote the first draft. WM provided clinical and experimental data, and modified the draft. XZ provided clinical and experimental data, and modified the draft. HK provided clinical and experimental data, and modified the draft. MA initiated the project, coordinated efforts between co-authors, and modified the draft. All authors read and approved the final manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.